



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	129.19
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	96.93 - 139.00
Volume	7

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 1, 2017

[FDA Grants Approval of IDHIFA® the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)

Jul 28, 2017

[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

Jul 27, 2017

[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)

Jul 25, 2017

[Celgene Corporation Announces Settlement of Civil Litigation](#)

Jul 5, 2017

[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

Financials [\[View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)

Oct 27, 2016

[Quarterly Report \(10-Q\)](#)